India · Delayed Price · Currency is INR Jagsonpal Pharmaceuticals Statistics
Total Valuation
NSE:JAGSNPHARM has a market cap or net worth of INR 15.22 billion. The enterprise value is 14.24 billion.
| Market Cap | 15.22B |
| Enterprise Value | 14.24B |
Important Dates
The last earnings date was Wednesday, July 29, 2026.
| Earnings Date | Jul 29, 2026 |
| Ex-Dividend Date | Sep 4, 2026 |
Share Statistics
NSE:JAGSNPHARM has 65.93 million shares outstanding. The number of shares has increased by 1.07% in one year.
| Current Share Class | 65.93M |
| Shares Outstanding | 65.93M |
| Shares Change (YoY) | +1.07% |
| Shares Change (QoQ) | -8.01% |
| Owned by Insiders (%) | 11.54% |
| Owned by Institutions (%) | 1.47% |
| Float | 15.34M |
Valuation Ratios
The trailing PE ratio is 34.43.
| PE Ratio | 34.43 |
| Forward PE | n/a |
| PS Ratio | 5.18 |
| PB Ratio | 5.51 |
| P/TBV Ratio | 7.68 |
| P/FCF Ratio | 32.61 |
| P/OCF Ratio | 32.51 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.96, with an EV/FCF ratio of 30.51.
| EV / Earnings | 31.31 |
| EV / Sales | 4.85 |
| EV / EBITDA | 22.96 |
| EV / EBIT | 27.45 |
| EV / FCF | 30.51 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.13 |
| Debt / FCF | 0.17 |
| Interest Coverage | 50.60 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 21.78% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 2.35% |
| Revenue Per Employee | 2.10M |
| Profits Per Employee | 325,061 |
| Employee Count | 1,399 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NSE:JAGSNPHARM has paid 152.91 million in taxes.
| Income Tax | 152.91M |
| Effective Tax Rate | 25.16% |
Stock Price Statistics
The stock price has decreased by -18.42% in the last 52 weeks. The beta is -0.35, so NSE:JAGSNPHARM's price volatility has been lower than the market average.
| Beta (5Y) | -0.35 |
| 52-Week Price Change | -18.42% |
| 50-Day Moving Average | 219.70 |
| 200-Day Moving Average | 200.81 |
| Relative Strength Index (RSI) | 55.25 |
| Average Volume (20 Days) | 801,897 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:JAGSNPHARM had revenue of INR 2.94 billion and earned 454.76 million in profits. Earnings per share was 6.70.
| Revenue | 2.94B |
| Gross Profit | 1.88B |
| Operating Income | 518.68M |
| Pretax Income | 607.67M |
| Net Income | 454.76M |
| EBITDA | 620.00M |
| EBIT | 518.68M |
| Earnings Per Share (EPS) | 6.70 |
Balance Sheet
The company has 1.06 billion in cash and 81.65 million in debt, with a net cash position of 979.55 million or 14.86 per share.
| Cash & Cash Equivalents | 1.06B |
| Total Debt | 81.65M |
| Net Cash | 979.55M |
| Net Cash Per Share | 14.86 |
| Equity (Book Value) | 2.76B |
| Book Value Per Share | 39.40 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 468.12 million and capital expenditures -1.48 million, giving a free cash flow of 466.64 million.
| Operating Cash Flow | 468.12M |
| Capital Expenditures | -1.48M |
| Depreciation & Amortization | 101.32M |
| Net Borrowing | -12.21M |
| Free Cash Flow | 466.64M |
| FCF Per Share | 7.08 |
Margins
Gross margin is 63.90%, with operating and profit margins of 17.65% and 15.48%.
| Gross Margin | 63.90% |
| Operating Margin | 17.65% |
| Pretax Margin | 20.68% |
| Profit Margin | 15.48% |
| EBITDA Margin | 21.10% |
| EBIT Margin | 17.65% |
| FCF Margin | 16.25% |
Dividends & Yields
This stock pays an annual dividend of 4.00, which amounts to a dividend yield of 1.73%.
| Dividend Per Share | 4.00 |
| Dividend Yield | 1.73% |
| Dividend Growth (YoY) | 60.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -1.07% |
| Shareholder Yield | 0.66% |
| Earnings Yield | 2.99% |
| FCF Yield | 3.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 8, 2025. It was a forward split with a ratio of 2.5.
| Last Split Date | Jan 8, 2025 |
| Split Type | Forward |
| Split Ratio | 2.5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |